Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.

@article{Walker2008CoronaryHD,
  title={Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.},
  author={Alexander Muir Walker and Carol E. Koro and Joan E Landon},
  journal={Pharmacoepidemiology and drug safety},
  year={2008},
  volume={17 8},
  pages={760-8}
}
BACKGROUND The risk of coronary heart disease (CHD) in users of antidiabetic agents must be quantified to permit reasoned therapeutic choices. OBJECTIVES To assess the risk of myocardial infarction (MI) and coronary revascularization (CR), in diabetic patients who began rosiglitazone, pioglitazone, metformin, or sulfonylureas. METHODS We conducted a retrospective cohort study of MI and CR in the PharMetrics database. We performed head-to-head comparisons using propensity-score-stratified… CONTINUE READING
18 Citations
7 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

Risk of stroke and myocardial infarction is reduced in patients with type 2 diabetes treated with pioglitazone: results of a retrospective claims-based study

  • Y Xu, C Vallarino, RW Baran, R. Spanheimer
  • Online abstract for the 43rd EASD Annual Meeting,
  • 2007
1 Excerpt

Study (UKPDS) Group

  • UK Prospective Diabete
  • Intensive blood-glucose control with…
  • 1998
1 Excerpt

Similar Papers

Loading similar papers…